Aclairo Pharmaceutical Development Group的封面图片
Aclairo Pharmaceutical Development Group

Aclairo Pharmaceutical Development Group

制药业

Sterling,Virginia 798 位关注者

providing strategic, scientific and regulatory support in pharmaceutical, device, and cell and gene therapy development

关于我们

Aclairo’s experience as FDA supervisors, reviewers, and industry strategists has forged a unique comprehension of the product-specific complexities of pharmaceutical development. The Aclairo advantage is our experience-based approach to providing strategic, scientific and regulatory services. This has proven to be our greatest asset in focusing and streamlining our clients’ development efforts, reducing both time and costs.

网站
http://www.Aclairo.com
所属行业
制药业
规模
11-50 人
总部
Sterling,Virginia
类型
私人持股
创立
2004
领域
Regulatory Services、Preclinical Project Management、Scientific Writing、Preclinical ADME、IND Preparation、CTD/eCTD Maintenance、Gap Analyses、Toxicology、Pharmacology和NDA/MAA preparation

地点

  • 主要

    45600 Terminal Dr

    Suite 200

    US,Virginia,Sterling,20166

    获取路线

Aclairo Pharmaceutical Development Group员工

动态

  • We have really enjoyed working with Jeff Harmon and his team on this project

    查看Jeff Harmon的档案

    Inspiring a Movement to Redefine Limits and Achieve the Extraordinary || Champion for the Impossible

    🌟 Empowering Excellence: Aclairo’s Training Initiative 🌟 I’m thrilled to share a project close to my heart—one designed to help the brilliant minds at Aclairo elevate their impact, both for each other and the clients they serve. We worked with their leadership to clearly define their culture and build a program to train their entire team and future new hires on it. Aclairo Pharmaceutical Development Group is a team of seasoned consultants and industry leaders, most of whom come from FDA or senior roles in pharma companies. They bring unparalleled expertise in drug development, toxicology, and clinical pharmacology/DMPK but what truly sets them apart is their commitment to collaboration and continuous growth. This training initiative is focused on unlocking that potential by: 1️⃣  Aligning personal and professional growth with Aclairo’s core values. 2️⃣  Building a culture of trust, authenticity, and mutual accountability. 3️⃣ Equipping the team to lead with impact, regardless of their seat. Our goal is simple but powerful: to help each individual show up as their best self, work together with clarity and purpose, and drive meaningful outcomes for the clients who depend on their expertise. It’s inspiring to witness a group of accomplished professionals embrace the opportunity to learn and grow together. By investing in their collective success, Aclairo is setting the standard for what exceptional consulting can look like. I’m excited for what’s ahead—and for the ripple effect this work will have on the industry and the clients Aclairo serves. What would be possible if you invested in your team by training them on your culture? DM me to chat about how we can help you do that.

    • 该图片无替代文字
  • Join EPL and Aclairo at the Upcoming ACT 45th Annual Meeting in Austin, TX. American College of Toxicology 45th Annual Meeting When: November 17th-20th, 2024 Where: JW Marriott, Austin, Tx Aclairo's own Dr. Emily Noonan Place will be co-chairing and speaking at a CE course. Safety Considerations for the Evaluation of Lipid-Based Nanoparticles (CE4) Date: Sunday, November 17th, 8:00am CT Aclairo Pharmaceutical Development Group, Inc. is proud to be a Co-Supporter of CE4 and will have the following participant at this session: Emily Noonan Place, PhD, MPH Session Co-Chair and Speaker

    • 该图片无替代文字
    • 该图片无替代文字
  • Join EPL and Aclairo for Our Industry-Hosted at EUROTOX 2024!! “Understanding Pathology Peer Reviews and Pathology Working Groups” Presented by: Heath Thomas, DVM, PhD, DACVP  President / Senior Consultant at Aclairo Pharmaceutical Development Group, Inc. Paul Snyder, DVM, PhD, DACVP, FIATP  Manager, EPL Southeast / Senior Pathologist at EPL Date:  Tuesday, September 10th; 12:00pm - 1:00pm Where: Tivoli Hotel & Congress Center, Copenhagen, Denmark Session Description The importance of and an overview of the pathology peer review process in toxicity studies for pharmaceutical and chemical development will be explained, along with various scenarios that may result from the process. Additionally, an overview and examples of how pathology working groups (PWGs) can overcome scientific roadblocks or answer regulatory questions in pharmaceutical and chemical development will be delivered.

相似主页

查看职位